StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Barclays on Merck (MRK): Terns deal shows Merck shifting toward 'more diversified onco strategy'
March 25, 2026 9:34 AM
Barclays analyst Emily Field reiterated an Overweight rating and $140.00 price target on Merck (NYSE: MRK)The analyst commented, "Merck’s ~$6.7bn ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
